Literature DB >> 1688569

Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

N Suzuki1, T Sakane, E G Engleman.   

Abstract

Although the presence of anti-DNA antibody is a hallmark of systemic lupus erythematosus (SLE), neither the subsets of B cells that secrete anti-DNA antibody nor the stimuli responsible for the induction of anti-DNA secretion is known. In particular, the role of CD5+ B cells in human SLE, a distinct subpopulation of antibody-secreting cells shown previously to be a source of anti-DNA antibody in murine models of SLE, is unknown. To approach these questions, we developed a sensitive enzyme-linked immunospot (ELIspot) assay to measure spontaneous secretion of antibody to single-stranded (ss) DNA, double-stranded (ds) DNA, tetanus toxoid, and polyclonal immunoglobulin (Ig) by purified CD5+ and CD5- B cells of 15 SLE patients and 15 healthy control subjects. The B cells of only 1 of 15 healthy subjects secreted a significant level of anti-ssDNA antibody, and none secreted anti-dsDNA. By contrast, in the majority of SLE patients both CD5+ and CD5- B cells secreted IgG and/or IgM anti-ssDNA as well as anti-dsDNA antibody. Further analysis of the anti-ssDNA response revealed that the level of IgG and IgM anti-DNA antibody secretion by CD5- B cells correlated closely with the level of polyclonal Ig production by the same subpopulation (r = 0.81 and 0.70, respectively). In contrast, production of anti-DNA by CD5+ B cells occurred independently of polyclonal Ig production by both CD5+ and CD5- B cell subpopulations. These results suggest that in human SLE there exist two anti-DNA antibody-producing B cell subpopulations with distinct induction mechanisms: one (CD5+), which independently secretes anti-DNA, and another (CD5-), which produces anti-DNA as an apparent consequence of polyclonal B cell activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688569      PMCID: PMC296411          DOI: 10.1172/JCI114418

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Phenotypic and functional characterization of human Leu1 (CD5) B cells.

Authors:  N Gadol; K A Ault
Journal:  Immunol Rev       Date:  1986-10       Impact factor: 12.988

2.  Development and physiology of Ly-1 B and its human homolog, Leu-1 B.

Authors:  R R Hardy; K Hayakawa
Journal:  Immunol Rev       Date:  1986-10       Impact factor: 12.988

3.  Reactivity of Leu-1+ tonsillar B cells to a high molecular weight B cell growth factor.

Authors:  Y Richard; C Leprince; B Dugas; D Treton; P Galanaud
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

Review 4.  Multigenic basis of autoimmune disease in New Zealand mice.

Authors:  T M Chused; K L McCoy; R B Lal; E M Brown; P J Baker
Journal:  Concepts Immunopathol       Date:  1987

5.  The role of clonal selection and somatic mutation in autoimmunity.

Authors:  M J Shlomchik; A Marshak-Rothstein; C B Wolfowicz; T L Rothstein; M G Weigert
Journal:  Nature       Date:  1987 Aug 27-Sep 2       Impact factor: 49.962

6.  Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice.

Authors:  D G Ando; F M Ebling; B H Hahn
Journal:  Arthritis Rheum       Date:  1986-09

7.  Rheumatoid factor secretion from human Leu-1+ B cells.

Authors:  R R Hardy; K Hayakawa; M Shimizu; K Yamasaki; T Kishimoto
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

8.  Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

Authors:  P Casali; S E Burastero; M Nakamura; G Inghirami; A L Notkins
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

9.  The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis.

Authors:  O Taniguchi; H Miyajima; T Hirano; M Noguchi; A Ueda; H Hashimoto; S Hirose; K Okumura
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

10.  Deficiencies in suppressor T cell activity seen in patients with active systemic lupus erythematosus are due to the dilution of normally functioning suppressor T cells by nonsuppressor T cells.

Authors:  T Sakane; S Takada; N Suzuki; T Tsuchida; Y Murakawa; Y Ueda
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  20 in total

1.  Age-dependent altered proportions in subpopulations of tonsillar lymphocytes.

Authors:  W Bergler; S Adam; H J Gross; K Hörmann; R Schwartz-Albiez
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Identification and analysis of a novel human surface CD5- B lymphocyte subset producing natural antibodies.

Authors:  M T Kasaian; H Ikematsu; P Casali
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

Review 3.  Hypergammaglobulinaemia and autoimmune rheumatic diseases.

Authors:  M R Ehrenstein; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 4.  Autoantibodies and antibacterial antibodies: from both sides now.

Authors:  R A Watts; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

5.  Establishment and characterization of a human B cell line producing IgG type antibodies to DNA.

Authors:  Y Maeda; F Horiuchi; J Miyatake; M Ohno; K Irimajiri; A Horiuchi
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

6.  Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus.

Authors:  N Suzuki; T Harada; S Mihara; T Sakane
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 7.  Anti-DNA antibodies. Their idiotypes and SLE.

Authors:  D Buskila; Y Shoenfeld
Journal:  Clin Rev Allergy       Date:  1994

8.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

9.  IL-4 down-regulates the surface expression of CD5 on B cells and inhibits spontaneous immunoglobulin and IgM-rheumatoid factor production in patients with rheumatoid arthritis.

Authors:  T Hidaka; A Kitani; M Hara; M Harigai; K Suzuki; Y Kawaguchi; T Ishizuka; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

10.  Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE).

Authors:  T Suzuki; N Suzuki; E G Engleman; Y Mizushima; T Sakane
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.